A rare case of cervical metastatis of glioblastoma after cranial tumor resection: case report and review of literature

Türk, Okan; Özdemir, Nuriye Güzin; Atçı, İbrahim Burak; Yılmaz, Hakan; Gunver, Feray; Antar, Veysel; Yılmaz, Adem

doi:10.1080/02688697.2020.1814994

Cited by 1 publication

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After removing 1 duplicate publication, 105 publications were excluded upon screening because of the following reasons: (1) the article did not present a case of GBM with metastatic disease outside the CNS—the brain and spinal cord; (2) the article was published in a language other than English, without an available English abstract; and (3) the article only provided a literature review of previously reported cases. A manual search of the references of 7 systematic reviews and/or meta-analysis17,31–37 yielded 14 additional papers, which were included for analysis. Analysis of the abstract/full-text of these 165 articles was performed, including collection of the molecular testing information.…”

Section: Methodsmentioning

confidence: 99%

TP53 Mutation and Extraneural Metastasis of Glioblastoma

Zhang¹,

Katsakhyan²,

LiVolsi³

et al. 2021

American Journal of Surgical Pathology

View full text Add to dashboard Cite

Extraneural metastases of glioblastoma (GBM), although rare, are becoming an increasingly recognized occurrence. Currently, the biological mechanism underlying this rare occurrence is not understood. To explore the potential genomic drivers of extraneural metastasis in GBM, we present the molecular features of 4 extraneural metastatic GBMs, along with a comprehensive review and analysis of previously reported cases that had available molecular characterization. In addition to our 4 cases, 42 patients from 35 publications are reviewed. To compare the molecular profiles between GBM cases with extraneural metastasis and the general GBM population, genomic data from GBM samples in The Cancer Genome Atlas (TCGA) database were also analyzed. We found that 64.5% (20/31) of the cases with extraneural metastasis that were tested for TP53 changes had at least 1 TP53 pathogenic variant detected in either 1 or both primary and metastatic tumors. In contrast, TP53 mutation was significantly less frequent in the unselected GBM from TCGA (22.6%, 56/248) (P=0.000). In addition, O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation was more common in unselected TCGA GBM cases (48.6%, 170/350) than in cases with extraneural metastasis (31.8%, 7/22), although not statistically significant. Although isocitrate dehydrogenase (IDH) mutation is a rare occurrence in high-grade astrocytomas, IDH-mutant grade 4 astrocytomas are at least as likely to metastasize as IDH wild-type GBMs; 3 metastatic cases definitively harbored an IDH1 (p.R132H) mutation in our analysis. Our findings not only provide potential biomarkers for earlier screening of extraneural metastasis, but could also suggest clues to understanding biological mechanisms underlying GBM metastasis, and for the development of therapeutic modalities.

show abstract

Section: Methodsmentioning

confidence: 99%